DewulfL. Patient engagement by Pharma—why and how? A framework for compliant patient engagement. Therapeutic Innovation & Regulatory Science. 2015;49(1):9–16.
2.
WalkerSMcAuslaneNLibertiLLeongJSalekS. A universal framework for the benefit-risk assessment of medicines: is this the way forward?Therapeutic Innovation & Regulatory Science. 2015;49(1):17–25.
3.
LevitanBPhillipsLDWalkerS. Structured approaches to benefit-risk assessment: a case study and the patient perspective. Therapeutic Innovation & Regulatory Science. 2014;48(5): 564–573.
4.
GeigerMJMehtaCTurnerJR. Clinical development approaches and statistical methodologies to prospectively assess the cardiovascular risk of new antidiabetic therapies for type 2 diabetes. Therapeutic Innovation & Regulatory Science. 2015;49(1):50–64.
